Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 9vHPV vaccine for prevention of persistent oral HPV infection in adult men
2019-003236-23Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection comparing 9vHPV vaccine with Placebo (2 arms). Primary endpoint: Incidence of HPV 16/18/31/33/45/52/58-related 6-month persistent oral infection. Started Jan 2020; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2019-003236-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003236-23.